Pharming announces first patient enrolled in pediatric clinical trial of leniolisib
Clinical trialsThe multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency.
Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe
Operational updatesPharming Group N.V. announces that the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has decided to shift its assessment of the Marketing Authorisation Application (MAA) for leniolisib to a standard review timetable.
Pharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
Clinical trialsV. Koneti Rao, MD, shared new evidence of long-term safety and hematologic response in patients who received leniolisib to treat APDS, a rare primary immunodeficiency. Interim analysis demonstrated leniolisib to be well tolerated and indicated the durability of the efficacy results seen in the Phase II/III randomized, controlled trial
Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH’s Blood
Clinical trialsLeniolisib was well tolerated and significant improvement over placebo was notable in the co-primary endpoints, reflecting a favorable impact on patients' immune dysregulation and deficiency. The peer-reviewed publication heightens international understanding of APDS, a rare and recently characterized immunodeficiency
Pharming Group announces presentation of new leniolisib data at 2022 ASH Annual Meeting
Conference attendancePresentation to highlight data from the ongoing long-term open-label extension study of leniolisib, a PI3Kδ inhibitor under investigation for APDS, a rare primary immunodeficiency.
Pharming to attend Credit Suisse 31st Annual Healthcare Conference
Conference attendancePharming Group N.V. announces that Pharming’s Chief Executive Officer, Sijmen de Vries, and Chief Medical Officer, Anurag Relan, will attend the Credit Suisse 31st Annual Healthcare Conference in Rancho Palos Verdes, California, November 7-10, 2022.
Pharming to present at Jefferies Healthcare Conference
Conference attendancePharming Group N.V. announces that its Chief Executive Officer, Sijmen de Vries, will present at the Jefferies Healthcare Conference in London, November 15-17, 2022.
Pharming to present at Stifel Healthcare Conference
Conference attendancePharming Group N.V. announces that its Chief Financial Officer, Jeroen Wakkerman, will present at the Stifel Healthcare Conference in New York, November 15-16, 2022.
Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisib
Operational updatesPharming Group N.V. announces today that its Marketing Authorisation Application (MAA) for leniolisib has been validated for scientific evaluation under an accelerated assessment by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).
Pharming Group reports earnings for the first nine months of 2022
Financial updatesPharming Group N.V. presents its preliminary, unaudited financial report for the first nine months ended September 30, 2022.